| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,200,000 |
| Market
Cap: |
281.00(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.13 - $7.84 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 15 |
| Insider 3/6 Months : 15.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
904,977 |
904,977 |
921,909 |
| Total Buy Value |
$0 |
$3,999,998 |
$3,999,998 |
$4,105,954 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
3 |
| Total Shares Sold |
10,601 |
23,175 |
31,212 |
31,212 |
| Total Sell Value |
$52,479 |
$108,434 |
$139,871 |
$139,871 |
| Total People Sold |
1 |
1 |
2 |
2 |
| Total Sell Transactions |
2 |
4 |
6 |
6 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Polaris Entrepreneurs Fund Vii, L.p. |
10% Owner |
– – • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
48,320 |
1.5 |
- |
|
| Polaris Entrepreneurs Fund Vii, L.p. |
10% Owner |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,186,653 |
22,167 |
|
- |
|
| Nashat Amir |
Director |
– • • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
48,320 |
2.25 |
- |
|
| Nashat Amir |
Director |
– • • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,186,653 |
22,167 |
|
- |
|
| Wuxi Pharmtech Healthcare Fund I L.p. |
10% Owner |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
931,857 |
931,857 |
|
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
D/D |
400,000 |
4,637,137 |
2.45 |
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
4,023,804 |
4,237,137 |
|
- |
|
| Kania Edwin M Jr |
10% Owner |
– – • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
918,664 |
1.5 |
- |
|
| Kania Edwin M Jr |
10% Owner |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
4,193,324 |
838,664 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2016-07-06 |
4 |
B |
$12.50 |
$5,409,325 |
D/D |
432,746 |
49,793 |
2.45 |
- |
|
| Green Jeremy |
10% Owner |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
466,182 |
40,420 |
|
- |
|
| Purcell Dennis J |
10% Owner |
– – • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
D/D |
400,000 |
908,565 |
2.45 |
- |
|
| Purcell Dennis J |
10% Owner |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
508,565 |
508,565 |
|
- |
|
| Wuxi Healthcare Ventures Ii, L.p. |
10% Owner |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
423,805 |
423,805 |
|
- |
|
| Bancel Stephane |
Director |
– • – |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
26,666 |
47,980 |
|
- |
|
| Simonian Nancy A |
President and CEO |
• • – |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
66,666 |
370,702 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
4,637,137 |
2.25 |
- |
|
| Nelsen Robert |
Director |
– • • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
4,023,804 |
4,237,137 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
120,000 |
40,000 |
|
- |
|
| Sharp Philip A |
Director |
– • – |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
146,666 |
146,666 |
|
- |
|
| Deerfield Private Design Fund Iii, L.p. |
Possible Members of 10% Group |
– – • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
628,566 |
1.5 |
- |
|
| Deerfield Private Design Fund Iii, L.p. |
Possible Members of 10% Group |
– – • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,695,220 |
508,566 |
|
- |
|
| Kania Edwin M Jr |
10% Owner |
– – • |
2016-06-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
213,332 |
|
- |
|
| Bancel Stephane |
Director |
– • – |
2016-06-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,314 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2016-06-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
213,333 |
|
- |
|
157 Records found
|
|
Page 6 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.15 (2.91%) 
